Steve Verdooner has led NeuroVision Imaging, Inc., in Sacramento, California, as chief executive officer for eight years. In this position, Steve Verdooner is responsible for all daily operations and long-term strategies at the neuroscience company.
This past summer, NeuroVision announced a successful conclusion to the company’s latest round of financing. The Series C round generated $12.2 million from investors, such as VSP Global, a vision care services company in Rancho Cordova, as well as funds controlled by Nikon, Corp., and Johnson & Johnson. This funding will help facilitate the validation and regulatory approval of NeuroVision’s non-invasive eye imaging system. Among various capabilities, the system scans for the presence of amyloid beta plaque, which is an early pathological sign of Alzheimer’s disease.
Speaking on behalf of the organization, Mr. Verdooner, described the round of funding as a testament to a shared confidence in and desire for the continued development of innovative health care tools and solutions.
